Guggenheim Assumes Tyra Biosciences at Buy, Announces Price Target of $55
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Debjit Chattopadhyay assumes Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $55.
Guggenheim analyst Debjit Chattopadhyay assumes Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $55.
